Chang Gung University, School of Nursing, Tao-Yuan, Taiwan, ROC; Department of Nursing, Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, ROC; Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Tao-Yuan, Taiwan, ROC.
Department of International Business, Soochow University, Taipei, Taiwan, ROC.
J Pain Symptom Manage. 2017 Nov;54(5):628-636.e2. doi: 10.1016/j.jpainsymman.2017.07.042. Epub 2017 Aug 4.
Stability of life-sustaining treatment (LST) preferences at end of life (EOL) has not been well established for terminally ill cancer patients nor have transition probabilities been explored between different types of preferences.
We assessed the stability of cancer patients' LST preferences at EOL by identifying distinct LST preference states and examining the probability of each state transitioning to other states between consecutive time points.
Stability of LST preferences (cardiopulmonary resuscitation, intensive care unit [ICU] care, cardiac massage, intubation with mechanical ventilation, intravenous nutrition support, and nasogastric tube feeding) was examined among 303 cancer patients in their last six months by hidden Markov modeling.
Six distinct LST preference states (initial size) were identified: uniformly preferring (8.3%), uniformly rejecting (33.8%), and uniformly uncertain about (20.5%) LST, favoring intravenous nutrition support but rejecting other treatments (19.9%), and favoring (3.6%) or uncertain about (14.0%) nutrition support and ICU care while rejecting other treatments. Shifts between LST preference states were relatively small between any two time points (transition probability of staying at the same state was 92.1% to 97.5%), except for the state characterized by uncertainty about nutrition support and ICU care while rejecting other treatments, in which 8.3% of patients shifted LST preferences toward uniform uncertainty at a subsequent assessment.
Our patients' LST preferences remained stable without prominent shifts toward preferring less aggressive LSTs even when death approached. Clarifying patients' understanding and expectations about LST efficacy and tailoring interventions to the unique needs of patients in each state may provide personalized EOL care.
终末期癌症患者的生命支持治疗(LST)偏好的稳定性在生命末期(EOL)尚未得到很好的确立,也没有探索过不同类型偏好之间的转移概率。
通过确定不同的 LST 偏好状态,检查癌症患者在 EOL 时 LST 偏好的稳定性,并研究每个状态在连续时间点之间向其他状态转移的概率,来评估癌症患者在 EOL 时 LST 偏好的稳定性。
通过隐藏马尔可夫模型,对 303 名处于生命最后六个月的癌症患者的 LST 偏好(心肺复苏、重症监护病房[ICU]护理、心脏按摩、机械通气插管、静脉营养支持和鼻胃管喂养)的稳定性进行了研究。
确定了六种不同的 LST 偏好状态(初始大小):均匀偏好(8.3%)、均匀拒绝(33.8%)和均匀不确定(20.5%)LST,支持静脉营养支持但拒绝其他治疗(19.9%),以及支持(3.6%)或不确定(14.0%)营养支持和 ICU 护理,同时拒绝其他治疗。在任何两个时间点之间,LST 偏好状态之间的转移相对较小(保持相同状态的转移概率为 92.1%至 97.5%),除了对营养支持和 ICU 护理不确定但同时拒绝其他治疗的状态,在随后的评估中,有 8.3%的患者将 LST 偏好转移到均匀不确定。
即使接近死亡,我们的患者的 LST 偏好仍然保持稳定,没有明显倾向于选择不那么积极的 LST。澄清患者对 LST 疗效的理解和期望,并根据每个状态患者的独特需求调整干预措施,可能为临终关怀提供个性化服务。